Get ready for exciting OPMD update by Axovant at the company's first ever R&D day -
"The agenda for R&D Day will include development updates, scientific and clinical insights from prominent physicians and researchers, and patient perspectives across Axovant’s gene therapy pipeline."
http://investors.axovant.com/news-releases/news-release-details/axovant-host-first-rd-day-march-29-2019Axovant insiders who bought multiple 10 million dollar tranches at $1 were rewarded two months later with (surprising) encouraging clinical results on the company's Parkinson's program.
Same pattern emerging for OPMD results on 29th March. Insiders have soaked up millions again at $1.50 -
"Filing shows Axovant holder Roivant bought
6.67M shares in offering…. shows majority shareholder Roivant Sciences bought just under 6.667M shares in a recent offering. That's linked to an offering of some
26.7M shares from the company last week, at
$1.50 each. Roivant used
cash on hand for the purchase, in order to
maintain its investment in Axovant. Roivant directly beneficially owns
58.15% of common shares, according to the filing."
